6 research outputs found
The Role of Cardiovascular Magnetic Resonance Imaging in the Assessment of Myocardial Fibrosis in Young and Veteran Athletes: Insights From a Meta-Analysis
Background: Cardiac magnetic resonance (CMR) combined with late
gadolinium enhancement (LGE) has revealed a non-negligible increased
incidence of myocardial fibrosis (MF) in athletes compared to healthy
sedentary controls.Objective: The aim of this systematic research and
meta-analysis is to investigate and present our perspective regarding
CMR indices in athletes compared to sedentary controls, including T1
values, myocardial extracellular volume (ECV) and positive LGE
indicative of non-specific fibrosis, also to discuss the differences
between young and veteran athletes.Methods: The protocol included
searching, up to October 2021, of MEDLINE, EMBASE, SPORTDiscus, Web of
Science and Cochrane databases for original studies assessing fibrosis
via CMR in athletes. A mean age of 40 years differentiated studiesâ
athletic populations to veteran and young.Results: The research yielded
14 studies including in total 1,312 individuals. There was a
statistically significant difference in LGE fibrosis between the 118/759
athletes and 16/553 controls (Z = 5.2, P < 0.001, I-2 = 0%, P-I =
0.45). Notably, LGE fibrosis differed significantly between 546 (14.6%)
veteran and 140 (25.7%) young athletes (P = 0.002). At 1.5T, T1 values
differed between 117 athletes and 48 controls (P < 0.0001). A
statistically significant difference was also shown at 3T (110 athletes
vs. 41 controls, P = 0.0004), as well as when pooling both 1.5T and 3T
populations (P < 0.00001). Mean ECV showed no statistically significant
difference between these groups.Conclusions: Based on currently
available data, we reported that overall LGE based non-specific fibrosis
and T1 values differ between athletes and sedentary controls, in
contrast to ECV values. Age of athletes seems to have impact on the
incidence of MF. Future prospective studies should focus on the
investigation of the underlying pathophysiological mechanisms
Trichohepatoenteric syndrome: A rare mutation in SKIV2L gene in the first Balkan reported case
Trichohepatoenteric syndrome or syndromic diarrhea is a rare and severe Mendelian autosomal recessive syndrome characterized by intractable diarrhea, facial and hair abnormalities, liver dysfunction, immunodeficiency and failure to thrive. It has been associated with mutations in TTC37 and SKIV2L genes, which encode proteins of the SKI complex that contributes to the cytosolic degradation of the messenger RNA by the cellâs exosome. We report a case of a male infant who suffered from typical symptoms and signs of trichohepatoenteric syndrome without immunodeficiency. The patientâs genetic testing showed a very rare mutation in SKIV2L geneâs 25 exons (p.Glu1038 fs*7 (c.3112_3140del)). Even though our patient was provided with total parenteral nutrition from birth, the childâs death in the third year of age highlights the severity of the disease and the poor prognosis of this particular type of genetic predisposition
Beat-to-Beat P-Wave Analysis Outperforms Conventional P-Wave Indices in Identifying Patients with a History of Paroxysmal Atrial Fibrillation during Sinus Rhythm
Early identification of patients at risk for paroxysmal atrial fibrillation (PAF) is essential to attain optimal treatment and a favorable prognosis. We compared the performance of a beat-to-beat (B2B) P-wave analysis with that of standard P-wave indices (SPWIs) in identifying patients prone to PAF. To this end, 12-lead ECG and 10 min vectorcardiogram (VCG) recordings were obtained from 33 consecutive, antiarrhythmic therapy naĂŻve patients, with a short history of low burden PAF, and from 56 age- and sex-matched individuals with no AF history. For both groups, SPWIs were calculated, while the VCG recordings were analyzed on a B2B basis, and the P-waves were classified to a primary or secondary morphology. Wavelet transform was used to further analyze P-wave signals of main morphology. Univariate analysis revealed that none of the SPWIs performed acceptably in PAF detection, while five B2B features reached an AUC above 0.7. Moreover, multivariate logistic regression analysis was used to develop two classifiersâone based on B2B analysis derived features and one using only SPWIs. The B2B classifier was found to be superior to SPWIs classifier; B2B AUC: 0.849 (0.754â0.917) vs. SPWIs AUC: 0.721 (0.613â0.813), p value: 0.041. Therefore, in the studied population, the proposed B2B P-wave analysis outperforms SPWIs in detecting patients with PAF while in sinus rhythm. This can be used in further clinical trials regarding the prognosis of such patients
The role of cardiopulmonary exercise testing in risk stratification and prognosis of atrial fibrillation: a scoping review of the literature
Cardiopulmonary exercise testing (CPET) is a significant tool for evaluating exercise capacity in healthy individuals and in various pulmonary and cardiovascular conditions, quantifying symptoms and predicting outcomes. Atrial fibrillation (AF) poses a significant burden on patients and health systems; a research marathon is ongoing for discovering the pathophysiologic substrate, natural history, prognostic tools and optimal treatment strategies for AF. Among the plethora of variables measured during CPET, there is a series of parameters of interest concerning AF. We conducted a scoping review aiming to identify significant CPET-related parameters linked to AF, as well as indicate the impact of other cardiac disease-related variables. We searched PubMed from its inception to 12 January 2022 for reports underlining the contribution of CPET in the assessment of patients with AF. Only clinical trials, observational studies and systematic reviews were included, while narrative reviews, expert opinions and other forms of manuscripts were excluded. In our scoping review, we report a group of heterogeneous, thus noteworthy parameters relevant to the potential contribution of CPET in AF. CPET helps phenotype AF populations, evaluates exercise capacity after cardioversion or catheter ablation, and assesses heart rate response to exercise; peak VO2 and VE/VCO2, commonly measured indices during CPET, also serve as prognostic tools in patients with AF and heart failure. CPET seems to hold a clinically important predictive value for future cardiovascular events both in patients with pre-existing cardiac conditions and in healthy individuals. CPET variables may play a fundamental role in the prediction of future AF-related events.</p
Blood groups and Rhesus status as potential predictors of outcomes in patients with cardiac resynchronisation therapy
Abstract Cardiac resynchronisation therapy (CRT) improves prognosis in patients with heart failure (HF) however the role of ABO blood groups and Rhesus factor are poorly understood. We hypothesise that blood groups may influence clinical and survival outcomes in HF patients undergoing CRT. A total of 499 patients with HF who fulfilled the criteria for CRT implantation were included. Primary outcome of all-cause mortality and/or heart transplant/left ventricular assist device was assessed over a median follow-up of 4.6 years (IQR 2.3â7.5). Online repositories were searched to provide biological context to the identified associations. Patients were divided into blood (O, A, B, and AB) and Rhesus factor (Rh-positive and Rh-negative) groups. Mean patient age was 66.4â±â12.8 years with a left ventricular ejection fraction of 29â±â11%. There were no baseline differences in age, gender, and cardioprotective medication. In a Cox proportional hazard multivariate model, only Rh-negative blood group was associated with a significant survival benefit (HR 0.68 [0.47â0.98], pâ=â0.040). No association was observed for the ABO blood group (HR 0.97 [0.76â1.23], pâ=â0.778). No significant interaction was observed with prevention, disease aetiology, and presence of defibrillator. Rhesus-related genes were associated with erythrocyte and platelet function, and cholesterol and glycated haemoglobin levels. Four drugs under development targeting RHD were identified (Rozrolimupab, Roledumab, Atorolimumab, and Morolimumab). Rhesus blood type was associated with better survival in HF patients with CRT. Further research into Rhesus-associated pathways and related drugs, namely whether there is a cardiac signal, is required